NICE: familial breast cancer consultation response content
The National Institute for Health and Care Excellence (NICE) produce best practice guidance for the NHS. When developing this guidance, they ask for experts and organisations to contribute by highlighting the relevant evidence in the area.
In September 2025 NICE released the draft scope for the update of their guidance on the initial assessment and genetic testing for familial breast cancer. Yorkshire Cancer Research responded to this consultation, drawing attention to the charity’s joint recent position statement on the use of PARPi as a risk reduction strategy and the PROTECT-C research study.
The use of PARP Inhibitors as Chemoprevention: A vision for the future
Yorkshire Cancer Research is one of seven leading cancer charities that have come together to explore a bold…
What the Government’s 10 Year Health Plan means for people in Yorkshire
On 3 July 2025, the Government published its long-awaited 10 Year Health Plan for England, setting out the…
Response to NICE perioperative care in adults: quality standards consultation
NICE’s quality standards set out the most important areas where health and care services can improve. For…